Top Infectious Disease News: Feb 15-21
Major advancements in infectious disease prevention are on the horizon, as Merck unveiled positive Phase 3 trial results for its RSV treatment, clesrovimab, aimed at protecting high-risk young children, and GSK presented new real-world effectiveness data for its Arexvy vaccine. Adding to these developments, the FDA has reversed its decision and will now review Moderna's investigational mRNA-1010 influenza vaccine, signaling a crucial step for its potential approval.